Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

Abstract The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also showed that a vector-prime protein boost comb...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Leila Eslamizar, Constantinos Petrovas, David J. Leggat, Kathryn Furr, Michelle L. Lifton, Gail Levine, Steven Ma, Christopher Fletez-Brant, Wesley Hoyland, Madhu Prabhakaran, Sandeep Narpala, Kristin Boswell, Takuya Yamamoto, Hua-Xin Liao, David Pickup, Elizabeth Ramsburg, Laura Sutherland, Adrian McDermott, Mario Roederer, David Montefiori, Richard A. Koup, Barton F. Haynes, Norman L. Letvin, Sampa Santra
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/63b38173c836479fba679161167f0413
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/63b38173c836479fba679161167f0413

Ejemplares similares